View by Specialty

Trending

PC0924Houry_Graphic_01_WEB
September 11, 2024
4 min read
Save

CDC data reveal three social drivers that influence suicide risk

Oncology News

SPONSORED CONTENT
Save
SPONSORED CONTENT
June 06, 2024
1 min read
Save

Trial of mirvetuximab soravtansine for ovarian cancer meets response rate endpoint

Trial of mirvetuximab soravtansine for ovarian cancer meets response rate endpoint

A trial investigating mirvetuximab soravtansine monotherapy in certain patients with platinum-sensitive ovarian cancer met its primary endpoint of improved objective response rate, according to the agent’s manufacturer.

SPONSORED CONTENT
June 04, 2024
2 min read
Save

High insulin levels may drive worse breast cancer outcomes for Black women

High insulin levels may drive worse breast cancer outcomes for Black women

BOSTON — Tumor samples from Black women diagnosed with triple-negative breast cancer expressed higher levels of insulin signaling than samples from white women, suggesting hyperinsulinemia may play a role in disease outcomes, data show.

Trending

PC0924Houry_Graphic_01_WEB
September 11, 2024
4 min read
Save

CDC data reveal three social drivers that influence suicide risk

SPONSORED CONTENT
June 03, 2024
3 min read
Save

Weight gain of 10% or more common among breast cancer survivors

Weight gain of 10% or more common among breast cancer survivors

BOSTON — Breast cancer survivors are more likely to have weight gain of 10% or more during follow-up compared with healthy controls, with the strongest predictors younger age at diagnosis and lower weight at baseline, data show.

SPONSORED CONTENT
June 02, 2024
3 min read
Save

Trastuzumab deruxtecan improves PFS in pretreated breast cancer

Trastuzumab deruxtecan improves PFS in pretreated breast cancer

CHICAGO — Trastuzumab deruxtecan extended PFS compared with standard chemotherapy for certain patients with pretreated breast cancer, according to findings presented at ASCO Annual Meeting.

SPONSORED CONTENT
May 28, 2024
1 min read
Save

Keytruda extends survival in high-risk triple negative breast cancer

Keytruda extends survival in high-risk triple negative breast cancer

A study assessing the efficacy of pembrolizumab met a key secondary endpoint of extending OS, in combination with chemotherapy, among patients with high-risk early-stage triple-negative breast cancer, according to the agent’s manufacturer.

SPONSORED CONTENT
May 24, 2024
3 min read
Save

Type of menopausal hormone therapy may influence cancer risk

Type of menopausal hormone therapy may influence cancer risk

CHICAGO — Cancer risk among women varied based on the type of menopausal hormone therapy they used, according to randomized study results scheduled for presentation at ASCO Annual Meeting.

SPONSORED CONTENT
May 23, 2024
3 min read
Save

HPV vaccination linked to lower risk for related cancers among men

HPV vaccination linked to lower risk for related cancers among men

Men vaccinated for HPV less frequently developed all related cancers, particularly head and neck cancers, according to findings scheduled for presentation at ASCO Annual Meeting.

SPONSORED CONTENT
May 23, 2024
2 min read
Save

Most young women can conceive, give birth after breast cancer treatment

Most young women can conceive, give birth after breast cancer treatment

CHICAGO — The majority of young breast cancer survivors who attempted pregnancy became pregnant, according to prospective study results scheduled for presentation at ASCO Annual Meeting.

SPONSORED CONTENT
May 23, 2024
2 min read
Save

School vaccination program increased HPV coverage for adolescents in France

School vaccination program increased HPV coverage for adolescents in France

In France, HPV vaccination at school significantly increased vaccination coverage among adolescents aged 11 to 14 years, according to study results published in JAMA Network Open.

SPONSORED CONTENT
May 22, 2024
3 min read
Save

Data show longer intervals between HPV testing likely safe

Data show longer intervals between HPV testing likely safe

A 5-year interval between cervical cancer screenings using HPV testing does not increase risk for cervical precancer detection compared with cytology every 3 years and may be a more effective screening method long term, researchers report.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails